INDIGO Biosciences today announced the launch of its transrepression assay service. This expands the company’s cell-based reporter assay capabilities for drug discovery teams studying pathway crosstalk, selective regulation, and transcription factor-mediated gene silencing.
This new service capability provides researchers with additional functional approaches to characterize the activity of compounds across nuclear receptor signaling and inflammatory pathways, and complements INDIGO’s existing receptor activation and pathway reporter assay services.
As part of this service, INDIGO Biosciences now supports GR/NF-κB transrepression studies, allowing customers to assess the interaction between glucocorticoid receptor signaling and NF-κB-driven transcriptional activity. in vitro Reporter assay format.
Trans-repression is a mechanism by which one transcription factor suppresses the activity of another transcription factor through crosstalk in signal transduction pathways, resulting in reduced transcriptional output. In the context of GR/NF-κB, this interaction provides important functional insight for compounds designed to modulate inflammatory signaling.
The expansion of our service capabilities to include transrepression assays reflects INDIGO’s continued commitment to providing researchers with biologically relevant tools for more complete compound characterization, and the addition of GR/NF-κB transrepression studies expands the ways our customers can investigate pathway-selective activities and generate deeper mechanistic insights to support discovery and development decisions. ”
Dr. Andrew Woodman, INDIGO Biosciences Laboratory Director
INDIGO’s transrepression assay services support functional evaluation of transcription factor-mediated gene repression in cell-based reporter assays, including potency, efficacy, and dose-response analyses. Additionally, INDIGO provides scientific support for study design, conduct, and data interpretation.
This service is suitable for anti-inflammatory drug discovery, glucocorticoid receptor research, nuclear receptor pharmacology, and broader studies of signal transduction pathway regulation.
By expanding the capabilities of its reporter assay services, INDIGO Biosciences continues to support drug discovery teams with biologically relevant assay approaches for compound profiling, mechanistic characterization, and informed decision-making across research and development programs.
